StocktoriaJasper Therapeutics, Inc. JSPR
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
0/9
Piotroski F — financial health
-40.54
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$83.9M | -$76.2M | -$68.9M | -$51.2M | -$36.8M |
| Net income | -$75.8M | -$71.3M | -$64.5M | -$37.7M | -$30.6M |
| Operating cash flow | -$77.2M | -$62.6M | -$52.1M | -$45.9M | -$33.7M |
| Total assets | $35.8M | $79.9M | $94.9M | $48.4M | $93.7M |
| Total liabilities | $31.6M | $18.2M | $16.5M | $12.4M | $24.1M |
| Shareholders' equity | $4.2M | $61.7M | $78.4M | $36.0M | $69.5M |
| Ratios | |||||
| Return on assets | -211.9% | -89.2% | -67.9% | -77.9% | -32.7% |
| Return on equity | -1826.1% | -115.6% | -82.2% | -104.7% | -44.1% |
| Current ratio | 2.62 | 4.98 | 7.19 | 5.91 | 10.95 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 177,500 | $155,526 |
Why these scores methodology →
Piotroski F-score: 0/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -40.54 (distress)
- Working capital / assets 0.599
- Retained earnings / assets -8.851
- EBIT / assets -2.344
- Equity / liabilities 0.131
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001788028 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.